23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million.

The stock had gained late Monday on news that the company plans to cut 40% of its workforce, but its latest 10-Q has 'going concern' language Shares of 23andMe Holding Co. fell 4% Tuesday after the ...

The stock of DNA testing company 23andMe (ME) dropped 59% Monday after filing for federal bankruptcy protection and the exit of its CEO, a dramatic collapse for a biotech company that once dazzled ...

SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file ...

23andMe Holding Co. (NASDAQ: ME) shares are headed toward zero as the DNA testing company prepares to go bankrupt. The CEO wants to remain in control of the assets. If you’re thinking about retiring ...

23andMe's battered stock sunk 59% Monday, after the DNA-testing company filed for bankruptcy and said Chief Executive Anne Wojcicki had resigned. Go deeper: 23andMe Files for Bankruptcy, as CEO Anne ...

On this episode of Stock Movers: - 23andMe (MEHCQ) shares are up as the bankrupt genetic-testing firm agreed to sell its data bank, which once contained DNA samples from about 15 million people, to ...

If you’ve ever used 23andMe to learn more about your genetics and ancestry, now may be the time to delete your data. The company, which grew rapidly in the 2010s by offering DNA-based ancestry and ...

Sometimes a public company has a controlling shareholder who wants to take it private by buying out all of the other shareholders, and that’s always messy.1 The controlling shareholder will to some ...

Shares of DNA testing company 23andMe Holding Co. (NASDAQ:ME) are trading lower in premarket on Monday after the firm filed for bankruptcy. The company has voluntarily filed for Chapter 11 bankruptcy ...

The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer for ...